Ligand Secures 47% Shareholder Support for XOMA Royalty Acquisition

summarizeSummary

Ligand Pharmaceuticals has secured voting agreements from XOMA Royalty Corp's major shareholders, representing 47.0% of outstanding common stock, significantly advancing its $739 million acquisition.

check_boxKey Events

• Significant Shareholder Support Secured

  Ligand Pharmaceuticals has entered into voting and support agreements with XOMA Royalty's officers, directors, and affiliated funds, representing approximately 47.0% of XOMA Royalty's outstanding common stock.

• Merger Approval Pathway Solidified

  These agreements commit the Supporting Stockholders to vote their shares in favor of the previously announced merger, significantly increasing the likelihood of the acquisition's completion.

• Acquisition Details Reaffirmed

  The filing reiterates the terms of the merger agreement, where XOMA Royalty shareholders will receive $39.00 per share in cash plus contingent value rights (CVRs).

auto_awesomeAnalysis

This Schedule 13D filing by Ligand Pharmaceuticals provides a critical update on its previously announced acquisition of XOMA Royalty Corporation. By entering into voting and support agreements with XOMA Royalty's officers, directors, and affiliated funds, Ligand has secured commitments representing approximately 47.0% of XOMA Royalty's outstanding common stock. This significant pre-vote commitment from key insiders and large shareholders substantially de-risks the merger's approval process, making the successful completion of the $739 million acquisition highly probable. For XOMA Royalty Corp shareholders, this solidifies the expectation of receiving the merger consideration, while Ligand investors can be more confident in the path to integrating XOMA's royalty assets.